Accuray signs new contract with Amerinet Accuray announced that it has signed a new three-year contract with Amerinet on the CyberKnife M6 and TomoTherapy H product portfolio. Under the new agreement, Accuray Incorporated's precise, leading-edge technologies, delivering the full range of radiation therapy and radiosurgery treatments, are immediately available to the hospitals that Amerinet serves.
Accuray backs FY16 revenue view of $395M-$410M, consensus $404.6M Adjusted EBITDA is expected to range between $25M-$35M. Accuray continues to expect that gross orders for the fiscal year will be approximately $295M, which would represent a 10% increase year over year. This financial guidance is unchanged from that provided on January 11.